Australia Refined its Psychedelic Therapy Framework — Here's What's Changed

Written by Hannah Barnett

Almost three years ago, Australia made history when the Therapeutic Goods Administration (TGA) approved access to MDMA for the treatment of post-traumatic stress disorder and psilocybin for treatment-resistant depression, making it the first country in the world to formally recognise these substances as medicines.

As with any significant and unprecedented regulatory decision, procedural and practical challenges have emerged since the ruling. Among the most pressing were those surrounding the requirements and application process for psychiatrists seeking approval as Authorised Prescribers (APs).

To address these, the TGA convened a targeted stakeholder consultation to discuss four key areas: competency requirements, therapy team composition, prescriber oversight, and treatment site standards.

The TGA recently released four key recommendations to clarify and refine how psychiatrists can access MDMA and psilocybin under the AP scheme.

Recommendation 1 – Psychiatrist Experience

Previously, no specific competency or experience pathway existed. Psychiatrists needed only HREC and TGA approval, with no prescribed standard for demonstrating expertise in psychedelic-assisted therapy itself.

Under the new framework, psychiatrists must demonstrate competency through one of two pathways: prior involvement in clinical trials of psychedelic-assisted psychotherapy, or supervised practice under an experienced AP psychiatrist. The dual pathway was introduced in recognition that relatively few psychiatrists have clinical trial experience, and as such restricting access to that group alone would have significantly limited patient access. The Royal Australian and New Zealand College of Psychiatrists (RANZCP) training framework now provides the benchmark for competency.

Recommendation 2 – Therapy Team Composition

The original rules required treatment to be delivered by "appropriately qualified and trained healthcare professionals" but offered no guidance on which professions qualified, what registration was required, or how a therapy team should be structured.

That vagueness has now been replaced with a structured but flexible approach. At least one member of the therapy dyad must hold registration with a specified National Board (e.g., as a clinical psychologist, medical practitioner, mental health nurse, or occupational therapist) with a scope of practice that includes psychedelic-assisted therapy. The AP psychiatrist takes responsibility for assessing the suitability of any additional team members, including unregistered practitioners such as counsellors or social workers. This broadens the available workforce while maintaining a clear line of clinical accountability.

Recommendation 3 – Prescriber Oversight

There was previously no defined requirement for the psychiatrist's physical presence during dosing, nor any explicit rules around who must conduct patient screening and informed consent. Rather than a rule being replaced, this was simply a gap, and an uncomfortable one given the vulnerability of the patient cohort.

The new recommendation closes that gap. The AP psychiatrist must personally conduct patient screening and informed consent, and must be physically present on-site during medicine administration. Continuous presence throughout the dosing day is not required, but the psychiatrist must be there at the point of administration to manage any adverse events in real time.

Recommendation 4 – Treatment Site Standards

The original framework required treatment to take place in a "controlled medical setting", but left it to ethics committees to determine what that meant in practice, which HRECs themselves said fell outside their remit.

The TGA has now set out clear minimum standards. Rather than mandating formal accreditation (which stakeholders flagged as prohibitively burdensome, particularly for smaller and regional providers), AP psychiatrists must demonstrate their site meets defined requirements: emergency resuscitation capability, secure Schedule 8 medicine storage, access to rescue medications, and proximity to an emergency department within 15 minutes. Crucially, treatment is no longer restricted to hospital settings, a change welcomed for improving accessibility and cultural appropriateness, particularly for First Nations patients and those in rural and regional areas.

Reflections from a Clinical Psychedelic Researcher

Dr. Rayann Zafar, Senior Researcher at Drug Science, found the the emphasis on competency-based training and supervised clinical experience to be “particularly noteworthy”:

“Psychedelic-therapies require skills that extend beyond conventional psychopharmacology, including expertise in patient selection, preparation, acute psychological support, and integration. Developing clear competency frameworks early will be critical if these treatments reach routine clinical practice.

The Australian model highlights the importance of defining the role of psychologists and therapists within multidisciplinary care teams. Psychedelic treatments sit at the intersection of biological and psychological interventions, and establishing clear standards for training, supervision, and scope of practice will help ensure consistency and quality of care."

He also reflected on the several important takeaways for the UK:

• Psychedelic medicines cannot be considered solely through the lens of the drug itself. Clinical outcomes are shaped by the interaction between pharmacology, therapeutic context, and healthcare delivery. As these treatments move closer to mainstream medicine, pharmacological expertise will need to be integrated with broader discussions around service design, safety monitoring, and real-world implementation.

• Australia’s approach acknowledges that it is possible to maintain high clinical standards while allowing environments that may be more conducive to therapeutic engagement and patient comfort. One of the ongoing debates internationally is how medicalised psychedelic therapy environments should be. While robust safety procedures, emergency preparedness, and appropriate governance are essential, there is growing recognition that treatment does not necessarily need to take place in a traditional hospital setting. This is especially relevant for rural communities and underserved populations, where access to specialist hospital services may be limited.

More broadly, Dr. Zafar notes, is that Australia’s experience highlights that regulatory approval is only one component of successful implementation. Questions around workforce development, accreditation, treatment environments, clinical governance, and equitable access may ultimately prove just as important as the medicines themselves.

“These are conversations the UK should be having now, rather than waiting until after any future regulatory decisions are made.”